Chimerix 10-K/A: Jazz Acquisition Details Revealed
| Field | Detail |
|---|---|
| Company | Chimerix Inc |
| Form Type | 10-K/A |
| Filed Date | Apr 16, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, tender-offer, amendment
Related Tickers: JAZZ
TL;DR
Chimerix 10-K/A: Jazz buying us for $935M ($8.55/share) - deal closing soon!
AI Summary
Chimerix, Inc. filed an amendment to its 2024 10-K on April 16, 2025, detailing its acquisition by Jazz Pharmaceuticals Public Limited Company. The deal, announced on March 4, 2025, involves Jazz acquiring Chimerix for approximately $935 million, or $8.55 per share, through a tender offer and subsequent merger.
Why It Matters
This filing provides crucial details for Chimerix shareholders regarding the acquisition by Jazz Pharmaceuticals, outlining the terms and conditions of the $935 million deal.
Risk Assessment
Risk Level: medium — The acquisition by Jazz Pharmaceuticals introduces regulatory and closing condition risks that could impact the completion of the deal.
Key Numbers
- $935 million — Acquisition Value (Total cash consideration Jazz Pharmaceuticals is paying for Chimerix.)
- $8.55 — Per Share Price (The cash amount Jazz Pharmaceuticals is offering for each share of Chimerix common stock.)
- 2024 — Fiscal Year End (The period covered by the original 10-K filing being amended.)
Key Players & Entities
- Chimerix, Inc. (company) — Filer of the 10-K/A
- Jazz Pharmaceuticals Public Limited Company (company) — Acquiring company
- $935 million (dollar_amount) — Total consideration for the acquisition
- $8.55 (dollar_amount) — Per share acquisition price
- March 4, 2025 (date) — Date of the Agreement and Plan of Merger
- March 21, 2025 (date) — Original filing date of the 10-K
- April 16, 2025 (date) — Filing date of this 10-K/A amendment
FAQ
What is the primary purpose of this 10-K/A filing?
This filing is an amendment to Chimerix, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, primarily to disclose details of the acquisition agreement with Jazz Pharmaceuticals.
When was the acquisition agreement between Chimerix and Jazz Pharmaceuticals entered into?
The Agreement and Plan of Merger was entered into on March 4, 2025.
What is the total value of the proposed acquisition of Chimerix by Jazz Pharmaceuticals?
The total consideration for the acquisition is approximately $935 million.
What is the per-share price offered by Jazz Pharmaceuticals for Chimerix?
Jazz Pharmaceuticals has agreed to acquire Chimerix for $8.55 per share in cash.
What are the key conditions for the completion of the merger?
The completion of the Merger remains subject to customary closing conditions, including the tender of a majority of the outstanding shares of Chimerix's voting common stock.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 16, 2025 regarding CHIMERIX INC.